Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...

根据提交给美国证券交易委员会的Form 4文件显示，Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL)的总法律顾问Kelley Shannon T最近出售了公司股票。Shannon于1月17日以平均每股273.41美元的价格出售了277股，总价值约75,734美元。这笔交易发生之际，这家市值63.9亿美元的公司股票在过去一周下跌了13%以上，尽管过去一年仍保持3 ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results.

Madrigal Pharmaceuticals, Inc.（纳斯达克代码：MDGL）的高级副总裁兼首席制药开发官Robert E. Waltermire最近出售了442股公司普通股。根据 InvestingPro 的分析，这家市值63.9亿美元、流动性强（流动比率为5.98）的生物制药公司尽管处于增长阶段，但仍保持着稳健的财务状况。这些股票以平均每股273.41美元的价格售出，总计约120,84 ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical ...

Show” correspondent Al Madrigal returned on Thursday night with a stinging message about immigrants in the United States.

2025年1月27日， Madrigal（MDGL）披露4笔公司内部人交易情况。董事Sibold William John于2025年1月24日卖出1584股。

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers." ...

A suspect was accused of sexually assaulting a woman during a home invasion robbery near UC Riverside Police said the suspect ...